Positives

• A patient who underwent 15 sessions of HELP apheresis followed by 6 sessions of plasmapheresis at the German clinic reported substantial symptom relief, attributed to filtering of microclots and SARS-CoV-2 spike proteins TCTMD.
  
  

Negatives

• Cardiology coverage at TCTMD raised concerns that patients are not being fully informed these therapies are experimental in Long COVID and that follow-up after expensive courses is often inadequate TCTMD.
  
  

Hurdles & Side Effects

• A typical apheresis course at the European clinics ranges from $10,000 to $20,000 for 3-5 weeks of therapy, including transportation, accommodation, and lab fees, putting it out of reach for most patients TCTMD.
  
  
• Apheresis requires central venous access and carries the usual risks of any extracorporeal blood-filtration procedure (citrate reactions, hypotension, infection at the line site), and patients without a UK-licensed equivalent must travel to Germany, Switzerland, or Cyprus to receive it.